Purpose To evaluate the survival of patients with diffuse large B-cell lymphoma (DLBCL) after chemotherapy (abbreviated as "chemotherapy") treated with Fuzheng Jiedu prescription, and to explore the association between lymphocyte subset levels and the survival of DLBCL patients after chemotherapy. method A total of 234 patients with DLBCL who had completed chemotherapy and achieved complete remission (CR) or partial remission (PR) were enrolled in the outpatient clinics and wards of the Department of Hematology of Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine and Oriental Hospital Affiliated to Shanghai Tongji University from January 1, 2013 to December 31, 2023. A cohort study design was adopted, and "whether or not to receive Fuzheng Jiedu prescription treatment for ≥6 months after chemotherapy" was used as an exposure factor. Patients who met this exposure factor were divided into the traditional Chinese medicine cohort, and patients who did not meet this exposure factor were divided into the observation cohort. The 1- and 2-year progression-free survival rates, overall survival rates, and duration of remission (DOR) of the two cohorts were compared, and the survival curves of the progression-free survival time and overall survival time of the two cohorts were drawn. Subgroup survival analysis was performed to further screen factors affecting disease progression and observe the effects of Fuzheng Jiedu prescription on the levels of lymphocyte subset counts in patients. result A total of 234 patients with DLBCL after chemotherapy were included in this study, including 126 cases in the TCM cohort and 108 cases in the observation cohort. Compared with the observation cohort, the 2-year progression-free survival rate, 2-year overall survival rate, and DOR of the TCM cohort were increased (all P < 0.05). The PFS of the TCM cohort was higher than that of the observation cohort [HR = 0.542, 95% CI (0.345-0.853), P < 0.01]. Subgroup analysis results showed that in the subgroups of age ≥ 60 years, Ann Arbor (AA) stage III-IV, and CD4 + < lower limit of normal range (LLN), the progression-free survival time of the TCM cohort was higher than that of the observation cohort (all P < 0.05). The results of COX regression showed that AA stage III-IV [HR = 2.180, 95% CI (1.064-4.466), P < 0.05] and CD4 + < LLN [HR = 2.840, 95% CI (1.253-6.434), P < 0.05] were independent risk factors for DLBCL disease progression after chemotherapy; the traditional Chinese medicine cohort was a protective factor [HR = 0.538, 95% CI (0.297-0.974), P < 0.05], which could reduce the risk of disease progression by 46.2%. The results of absolute count analysis of lymphocyte subsets showed that in the TCM cohort, CD3 +, CD4 +, and CD19 + were higher 2 years after the end of induction chemotherapy than at the end of induction chemotherapy (all P < 0.05). When the two cohorts were compared, the difference in CD3 + and CD4 + in the TCM cohort widened, while that in the observation cohort narrowed . The difference in changes between the two cohorts was statistically significant (all P < 0.05). in conclusion Maintenance therapy with Fuzheng Jiedu prescription can improve the survival rate and prolong the survival time of DLBCL patients after chemotherapy, and the benefits are more obvious in people aged ≥60 years, AA stage III-IV, and CD4 + < LLN. Fuzheng Jiedu prescription can significantly reduce the risk of disease progression in patients with DLBCL after chemotherapy and improve the level of immune cells in patients. After the end of Western medicine chemotherapy, sequential maintenance therapy with Fuzheng Jiedu prescription can bring better therapeutic effects to DLBCL patients. Objective To evaluate the survival of patients with diffuse large B-cell lymphoma (DLBCL) after chemotherapy using Fuzheng Jiedu Formula and to explore the intrinsic correlation between the lymphocyte subset level and the survival of patients with DLBCL. Methods A total of 234 patients with DLBCL who had completed chemotherapy and achieved complete or partial response in the Department of Hematology, Longhua Hospital Shanghai University of Traditional Chinese Medicine and Shanghai East Hospital, Tongji University from January 1, 2013, to December 31, 2023, were recruited. A cohort study design was adopted, with "whether to receive continuous Fuzheng Jiedu Formula treatment for ≥ 6 months after chemotherapy" as the exposed factor. Patients meeting this exposed factor were divided into the traditional Chinese medicine (TCM) cohort, whereas those who did not meet this exposed factor were divided into the observation cohort. The 1- and 2-year progression-free survival (PFS) rate, overall survival (OS) rate, and duration of response (DOR) of the two cohorts were compared. The survival curves of PFS and OS of the two cohorts were drawn, and subgroup survival analysis was performed to determine factors affecting disease progression. The effect of Fuzheng Jiedu Formula on lymphocyte subset count level was observed. Results The study included 126 and 108 patients in the TCM and observation cohorts, respectively. Compared with the observation cohort, the 2-year PFS rate, 2-year OS rate, and DOR were increased in the TCM cohort (P<0.05). The PFS in the TCM cohort was higher than that in the observation cohort [HR=0.542, 95%CI(0.345-0.853), P<0.01]. The result of subgroup analysis showed that PFS in the TCM cohort was higher than that in the observation cohort in the age ≥60 years, AA stage III-IV, CD4+